© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Veradermics, Incorporated (MANE) stock declined over -8.32%, trading at $73.80 on NYSE, down from the previous close of $80.50. The stock opened at $80.90, fluctuating between $72.48 and $80.90 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 72.00 | 75.95 | 69.47 | 74.99 | 476.6K |
| Apr 13, 2026 | 69.55 | 72.47 | 68.30 | 71.36 | 656.73K |
| Apr 10, 2026 | 60.06 | 69.57 | 59.24 | 68.80 | 631.45K |
| Apr 09, 2026 | 58.14 | 60.44 | 57.20 | 59.98 | 130.76K |
| Apr 08, 2026 | 57.73 | 58.76 | 53.68 | 58.04 | 421.54K |
| Apr 07, 2026 | 63.81 | 63.82 | 56.59 | 56.71 | 349.82K |
| Apr 06, 2026 | 64.43 | 65.29 | 61.55 | 63.82 | 226.12K |
| Apr 02, 2026 | 57.51 | 64.19 | 57.45 | 64.19 | 839.49K |
| Apr 01, 2026 | 65.14 | 66.50 | 57.87 | 58.78 | 623.24K |
| Mar 31, 2026 | 61.44 | 66.53 | 59.30 | 63.15 | 805.94K |
| Mar 30, 2026 | 64.85 | 66.07 | 54.77 | 60.85 | 599.33K |
| Mar 27, 2026 | 67.01 | 69.01 | 65.17 | 65.53 | 261.73K |
| Mar 25, 2026 | 63.65 | 66.54 | 62.28 | 65.56 | 455.83K |
| Mar 24, 2026 | 62.53 | 66.20 | 62.53 | 63.49 | 536.79K |
| Mar 23, 2026 | 59.01 | 62.86 | 58.96 | 61.92 | 291.83K |
| Mar 20, 2026 | 55.70 | 59.61 | 55.05 | 58.89 | 1.32M |
| Mar 19, 2026 | 57.88 | 59.60 | 55.00 | 56.91 | 620.39K |
| Mar 18, 2026 | 60.50 | 63.03 | 58.40 | 59.01 | 530.91K |
| Mar 17, 2026 | 56.45 | 62.56 | 55.99 | 61.07 | 573.33K |
| Mar 16, 2026 | 52.62 | 58.60 | 52.62 | 56.95 | 339.95K |
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
| Employees | 0 |
| Beta | 0 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |